Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT1 | P34896 | 2/20 | 0.33 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | DUSP10 | Q9Y6W6 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 2/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31292345 | 0.83 | PLCG1 (0.40) | CCR1HCRTR1HCRTR2RXRAGRIN1 | |
| SCHEMBL31292380 | 0.83 | KDM5A (0.35) | HCRTR1HCRTR2SLC22A12RXRAGRIN1 | |
| SCHEMBL12341062 | 0.80 | CCR1 (0.39) | CCR1HCRTR1HCRTR2RXRAGRIN1 | |
| SCHEMBL23355549 | 0.79 | HCRTR1 (0.40) | CCR1HCRTR1HCRTR2RXRAGRIN1 | |
| SCHEMBL29215947 | 0.76 | MAP4K4 (0.33) | PPARASLC22A12 | |
| SCHEMBL30496847 | 0.76 | MAP4K4 (0.33) | PPARASLC22A12 | |
| SCHEMBL3662853 | 0.73 | MALT1 (0.42) | CCR1RXRAGRIN1GRIN2B | |
| SCHEMBL23355691 | 0.71 | NPSR1 (0.36) | SHMT1CCR1HCRTR1HCRTR2PPARG | |
| SCHEMBL31292354 | 0.69 | PLCG1 (0.39) | RXRAGRIN1GRIN2B | |
| SCHEMBL896386 | 0.69 | PARP1 (0.35) | HCRTR1HCRTR2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | SHMT1 1277/4885SHMT2 868/4885CCR1 3433/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | SHMT1 1285/4885SHMT2 871/4885CCR1 3456/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | SHMT1 1277/4885SHMT2 868/4885CCR1 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.